SCHEMBL6991291

SCHEMBL6991291

CC(C)(C)[Si](C)(C)OC(CN1CCC(Cc2ccccc2)CC1)C(N)=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
CARM1 Q86X55 1/20 0.47
PRMT6 Q96LA8 1/20 0.47
GAA P10253 1/20 0.47
ABCB1 P08183 2/20 0.47
DRD4 P21917 2/20 0.47
GRIN2D O15399 2/20 0.46
GRIN3B O60391 2/20 0.46
ADRA1D P25100 2/20 0.46
ADRA1A P35348 2/20 0.46
ADRA1B P35368 2/20 0.46
GRIN1 Q05586 2/20 0.46
GRIN2A Q12879 2/20 0.46
GRIN2B Q13224 2/20 0.46
GRIN2C Q14957 2/20 0.46
GRIN3A Q8TCU5 2/20 0.46
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
HTT P42858 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7107010 0.90 GMNN (0.46) MEN1KMT2ADRD4GRIN1GRIN2B
SCHEMBL6986786 0.81 GRIN2D (0.51) MEN1KMT2ACARM1PRMT6DRD4
SCHEMBL6998498 0.81 MEN1 (0.51) MEN1KMT2ACARM1PRMT6DRD4
SCHEMBL6989963 0.77 GRIN2D (0.47) MEN1KMT2ACARM1PRMT6ABCB1
SCHEMBL6986592 0.75 MEN1 (0.64) MEN1KMT2ACARM1PRMT6GAA
SCHEMBL21099137 0.75 SRR (0.47)
SCHEMBL28993898 0.74 MEN1 (0.55) MEN1KMT2ACARM1PRMT6GAA
SCHEMBL6998177 0.73 MEN1 (0.47) MEN1KMT2ACARM1PRMT6GAA
SCHEMBL6997026 0.73 MEN1 (0.46) MEN1KMT2ACARM1PRMT6GRIN2D
SCHEMBL6993151 0.71 GRIN2B (0.46) MEN1KMT2ADRD4GRIN2DGRIN3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6642256-B2 Brain disorders, psychological disorders, antiischemic agents, central nervous system disorders WARNER-LAMBERT COMPANY LLC 2003-11-04 US disclosed
EP-1345935-A2 PIPERIDINE DERIVATIVES AS SUBTYPE SELECTIVE N-METHYL-D-ASPARTATE ANTAGONISTS Warner-Lambert Company LLC (US) 2003-09-24 EP disclosed
US-20030018021-A1 Piperidine derivatives as subtype selective N-methyl-D-aspartate antagonists KORNBERG BRIAN EDWARD (US) 2003-01-23 US disclosed
WO-2002050070-A2 PIPERIDINE DERIVATIVES AS SUBTYPE SELECTIVE N-METHYL-D-ASPARTATE ANTAGONISTS WARNER-LAMBERT COMPANY LLC (US) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018021-A1 Piperidine derivatives as subtype selective N-methyl-D-aspartate antagonists GRIN1, OPRD1, OPRM1 MEN1 2014/4885KMT2A 1598/4885CARM1 683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.